Abstract
The discovery of a defective gene that increases the risk of bowel cancer development will help focus screening and treatment efforts on those individuals at greatest risk. Collaborative work between researchers from the US, Finland and New Zealand has shed light on the incidence and nature of the defect, and will lead to the development of an effective screening test. Inpharma spoke with Professor Jeremy Jass from the University of Auckland, New Zealand, on the implications of this work.
Rights and permissions
About this article
Cite this article
Higgins, G. Knowing who’s at risk - a genetic clue to bowel cancer. Inpharma Wkly. 923, 3 (1994). https://doi.org/10.2165/00128413-199409230-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199409230-00003